Hunter of the Lost Treasures

The Evolution Of Playstation
July 21, 2017
Include Love To Your Wedding event With Developer Wedding celebration Cakes
August 11, 2017
Show all

Berlin – He is the shooting star on the OTC sky: Dr. In recent years, Clemens Fischer has worked with Naturwohl and Dr. Fishermen’s health products, two producers were struck out of the soil, whose joint sales approached the 150 million euro mark. His concept: to help old treasures to a new splendor. His goal: to open up new buyer strata for himself and the pharmacies – and perhaps also get out of the way. Lactostop and Yokebe have already been sold; Deseo, Taumea, Kijimea and Rubax Mono may continue to grow under his responsibility. Further categories are planned.

Fischer, born in 1975, studied medicine and business administration. In 2001, he joined Novartis as a product manager. His first project on parallel trade is met with interest at the then global pharmacy company Thomas Ebeling, who takes the emerging young managers under his wing. The Harvard MBA in his pocket, Fischer is directly assigned to the management, is responsible for the strategy and the cardiovascular system with preparations such as Rasilez, Galvus, Eucreas, Myfortic, Neoral and Diovan Mono-Embolex.

At the same time he is active as a company consultant: He is responsible for the introduction of eryhtropoetin, the Hamburg-based biotechnology company Evotec, in the portfolio strategy. Novartis is helping to sell various OTC brands, and in the marketing of Voltaren/Voltaflex, he is also helping his colleagues from self-medication. For the DKV, he elaborates a reimport strategy and advises AOK Niedersachsen on contract management. The financial investor TVM Capital (Riemser) is also one of its customers.

In 2007, he developed a concept to address physicians online. “I’ve always realized that the Internet is a big deal,” he remembers. Novartis takes over the initial funding; Officially, however, fishermen go out to keep the risks for the group low. At the same time, he draws up a rating portal for physicians, which Novartis also takes over after completion of the project, but immediately struck.

Comments are closed.

Buy now